Information  X 
Enter a valid email address

Verona Pharma plc (VRP)

  Print      Mail a friend

Thursday 16 April, 2020

Verona Pharma plc

Verona Pharma plc: Results of AGM

Verona Pharma plc: Results of AGM

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly approved by shareholders by way of a poll. The results of the poll are available on the Investors section of the Company’s website, www.veronapharma.com.

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently evaluating three formulations of ensifentrine for the treatment of COPD in Phase 2 clinical trials: nebulized, dry powder inhaler, and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Victoria Stewart, Director of Communications [email protected]
   
N+1 Singer Tel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
Aubrey Powell / George Tzimas / Iqra
Amin (Corporate Finance)
Tom Salvesen (Corporate Broking)
 
   
Optimum Strategic Communications
(European Media and Investor Enquiries)
Tel: +44 (0)20 3950 9144
[email protected]
Mary Clark / Eva Haas / Hollie Vile  
   
Argot Partners
(US Investor Enquiries)
Tel: +1 212-600-1902
[email protected]
Stephanie Marks / Kimberly Minarovich /
Michael Barron
 

a d v e r t i s e m e n t